Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1 [Yahoo! Finance]
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: Yahoo! Finance
The figure improved from the year-ago quarter's loss of 21 cents. The quarter's adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization. Revenues Total revenues rose 12% year over year to $202.2 million in the quarter under review. The figure topped the Zacks Consensus Estimate by 4.6%. Testing volumes rose 9% year over year. Quarter in Detail Hereditary Cancer testing revenues rose 16% year over year to $88.1 million. Pharmacogenomics testing revenues were $38.9 million, up 21% year over year. Tumor Profiling testing revenues fell 17% year over year to $30.9 million. Prenatal testing revenues came in at $44.3 million, up 22% year over year. Margin Trends The gross margin in the quarter under review expanded 72 basis points (bps) to 68.1%. Research and development expenses rose 10.7% year over year to $24.9 million. SG&A expenses fell 7.3% to $140.6 million in the reported quarter. The adjuste
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerGlobeNewswire
- Genomic Cancer Panel and Profiling Market Report 2024. by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size [Yahoo! Finance]Yahoo! Finance
- Almost 1 in 2 Americans feel they've lost time to poor mental health, survey says. It's worse for people with depression or anxiety [Yahoo! Finance]Yahoo! Finance
- Almost 1 in 2 Americans feel they've lost time to poor mental health, survey says. It's worse for people with depression or anxiety [Fortune]Fortune
MYGN
Earnings
- 5/7/24 - Beat
MYGN
Analyst Actions
- 5/8/24 - Leerink Partners
MYGN
Sec Filings
- 5/15/24 - Form 4
- 5/15/24 - Form 4
- 5/15/24 - Form 144
- MYGN's page on the SEC website